Effect of Guided Imagery on Chemotherapy-related Nausea and Vomiting
Effect of Guided Imagery on Chemotherapy-related Nausea and Vomiting in Pediatric Oncology Patients: a Randomized Controlled Trial
The goal of this randomized controlled study is to assess the effect of guided imagery on chemotherapy-related nausea and vomiting in pediatric oncology patients.
Participants will receive either guided imagery+routine care or routine care. The researchers will compare nausea and vomiting and vital signs between groups.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Ayşe Ay, RN, PhD
- Phone Number: +905073560214
- Email: ayse0526@gmail.com
Study Contact Backup
- Name: Yağmur Sezer Efe, RN, PhD
- Phone Number: +905064378562
- Email: ysezerefe@gmail.com
Study Locations
-
-
Ankara
-
Ankara, Ankara, Turkey (Türkiye), 06100
- Recruiting
- Hacettepe University İhsan Doğramacı Hospital
-
Contact:
- Şule Ünal Cangül, MD, Prof
- Phone Number: +905325263749
- Email: suleunal@hacettepe.edu.tr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 7 to 18 years old,
- who will receive intravenous chemotherapy,
- no cognitive or neurological disease that would prevent communication,
- receiving a chemotherapy protocol with a high or moderate emetogenic effect according to the MASCC/ESMO Antiemetic Guideline Classification,
- no verbal, visual and auditory communication disabilities (ability to speak Turkish, no mental deficiency),
- children whose parents and themselves volunteered to participate in the study
Exclusion Criteria:
- Children receiving radiotherapy,
- taking ginger powder or vitamins to reduce nausea,
- children who did not want to participate in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: Control
Participants will receive routine care.
|
|
|
Experimental: Guided imagery group
Participants will receive guided imagery intervention.
|
The children in the experimental group will listen to the first part of the 'Guided Imagery CD' prepared by the Turkish Psychological Association for relaxation 30 minutes before the chemotherapy infusion starts.
The suggestions given in the first part of the CD will help the patients relax and focus their attention on their breathing.
Patients will be positioned in a supine or semi-fowler position and will listen to the CD with headphones from a laptop.
Once the chemotherapy infusion starts, relaxing light background music with the sound of a river or sea will be played based on the patients' preference, and imagery will be applied to the patients.
Patients will be encouraged to think of various images, such as imagining that the treatment is over, visualizing themselves as much healthier and recovering quickly, returning to their old life, and doing whatever they want to do first after recovery.
If there is an object, person, event, situation, or food that will make them feel good,
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Nausea and vomiting
Time Frame: 30 minutes before the procedure, halfway through the chemotherapy infusion, immediately after the procedure, and for the first 24 hours after the end of chemotherapy
|
Nausea and Vomiting Thermometer Scale in Children with Cancer is a 5-likert type scale.
An increase in the score indicates an increase in the degree of nausea and vomiting experienced by children with cancer.
|
30 minutes before the procedure, halfway through the chemotherapy infusion, immediately after the procedure, and for the first 24 hours after the end of chemotherapy
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Oxygen saturation
Time Frame: change from baseline 60 minutes of chemotherapy infusion
|
Maintaining or normalizing oxygen saturation within normal range (between 95%-100% by pulse oximetry)
|
change from baseline 60 minutes of chemotherapy infusion
|
|
Heart rate
Time Frame: 30 minutes before the procedure, halfway through the chemotherapy infusion, and immediately after the procedure,
|
Maintaining or normalizing heart rate within normal range (60 to 110 bpm)
|
30 minutes before the procedure, halfway through the chemotherapy infusion, and immediately after the procedure,
|
|
Systolic and diastolic blood pressure
Time Frame: 30 minutes before the procedure, halfway through the chemotherapy infusion, and immediately after the procedure
|
Maintaining or normalizing systolic and blood pressure within normal range (systolic: 90-120 mmHg; diastolic 60-80 mmHg)
|
30 minutes before the procedure, halfway through the chemotherapy infusion, and immediately after the procedure
|
|
Respiratory rate
Time Frame: 30 minutes before the procedure, halfway through the chemotherapy infusion, and immediately after the procedure
|
Maintaining or normalizing respiratory rate within normal range (18-30 breath per minute)
|
30 minutes before the procedure, halfway through the chemotherapy infusion, and immediately after the procedure
|
|
Body temperature
Time Frame: 30 minutes before the procedure, halfway through the chemotherapy infusion, and immediately after the procedure
|
Maintaining or normalizing body temperature within normal range (36-37 C° in tympanic measurement)
|
30 minutes before the procedure, halfway through the chemotherapy infusion, and immediately after the procedure
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Ayşe Ay, RN, PhD, Baskent University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- KA23/180
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.